胸腺因子D治疗慢性乙型肝炎前瞻性研究

目的　了解胸腺因子D治疗慢性乙型肝炎远期疗效 ,有无延迟效应。方法　 742例慢性乙型肝炎患者分成 2组进行治疗 ,治疗组 5 72例 ,接受小剂量或大剂量胸腺因子D治疗 3个月 ,小剂量为 10mg ,肌注 ,每日或隔日一次 ,大剂量为5 0mg ,静滴 ,每日或隔日一次。对照组 170例 ,接受综合治疗。治疗前两组临床生化特征具有可比性。治疗结束后随访0 .5～ 5年。以病毒复制标志HBeAg转阴为应答 ,分别于治疗结束和随访结束时判断疗效。 结果　治疗结束时治疗组应答率 2 7.73 % ,对照组 9.86% (P <0 .0 0 5 ) ;随访结束时治疗组应答率 43 .0 2 % ,对照组 13 .90 % (P <0 .0 0 5 )。结论　胸腺因子D治疗慢性乙型肝炎有延迟效应

Prospective Study on Thymic Factor D Treating Patients with Chronic Hepatitis B

Objective To elucidate the long time efficacy of thymic factor D(TFD),and to observe if it has a delayed effect.Method 742 patients with chronic hepatitis B were allocated to 2 groups:(1)Group A(n=572) received a 3 month course therapy with either a small dose of 10mg TFD intramuscular injection once a day or every other day,or a large dose of 50mg ivgtt once a day or every other day.(2)Group B(n=170) served as control without specific treatment.The two groups were comparable in clinicochemical features.Patients were followed up for 0.5～5 years.The complete virological response was defined as the loss of serum hepatitis B e antigen(HBeAg).The therapeutic effect was evaluated at the end of both treatment and follow up.Results The complete virological response rate was higher in group A(27.73%) than that in group B(9.86%) at the end of therapy( P <0.005).The complete response accumulated gradually during follow up.The complete response rate in group A was 43.02% whereas 13.90% in group B at the end of follow up( P <0.005).Conclusion There is a delayed effect of TFD therapy in the patients with chronic hepatitis B.